There's a wealth of mobile apps out there turning our everyday habits into numbers, and J&J, pharma's design pioneer, has some ideas on how to use them.
There are plenty of mobile apps out there that translate our health activities into numbers. Using apps and other hardware, patients these days are tracking how--and how much--they sleep, eat and walk. But how can pharma capitalize on this "quantified self" phenomenon? Johnson & Johnson has a few ideas.
Not satisfied with being the world's biggest health-care products company, Johnson & Johnson will expand its already dominant presence in China later this year when it introduces plates and screws manufactured in the country at its Suzhou facility.
California has decided to lay the responsibility for opioid overdoses, and even a resurgence in heroin use, at the feet of the drugmakers, accusing them in a lawsuit of reaping huge profits while turning a large swath of people into drug addicts.
Michael Orsinger, chairman of Johnson & Johnson's DePuy Synthes orthopedics unit, said May 22 that customers are demanding a "one stop shop" approach toward implants, predicting that it will drive continued consolidation in the industry.
With all of the pharma layoffs, lots of folks are looking for a job in the industry. So where are the best places to work? Johnson & Johnson and Novartis if you want to work for a large company. Biogen Idec, Gilead or perhaps Novo Nordisk if you prefer more of a midsize drugmaker.
Janssen, the biotech unit of Johnson & Johnson, is looking beyond just pharmaceuticals with its latest life sciences incubator, seeking out medical device and diagnostics startups to fill its planned lab space.
Johnson & Johnson's Janssen arm is planning to open another biotech incubator, this time setting its sights on South San Francisco in hopes of finding a few promising drug developers.
It turns out that Boehringer Ingelheim's popular anticoagulant Pradaxa is safer than many people think. That is the finding of the FDA after taking another look at the side effects of the drug compared to the old standard warfarin and this time looking at a much larger and older patient base.
Over the past few years, the bottom-line number on R&D spending among the big 10 pharma companies--about $70 billion--has remained about the same. But behind the steady collective figure lies...